<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04943653</url>
  </required_header>
  <id_info>
    <org_study_id>KC20MISF0813</org_study_id>
    <nct_id>NCT04943653</nct_id>
  </id_info>
  <brief_title>Intraperitoneal Paclitaxel With XELOX in Gastric Cancer With Peritoneal Metastasis</brief_title>
  <acronym>IPXELOX</acronym>
  <official_title>Phase I,II Study of First Line Intraperitoneal Paclitaxel With Systemic Capecitabine and Oxaliplatin Combination Therapy in Patients With Advanced Gastric Cancer With Peritoneal Metastasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul St. Mary's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul St. Mary's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      IPXELOX will investigate the safety, tolerability, and antitumor activity of intraperitoneal&#xD;
      paclitaxel in combination with chemotherapy in patients with advanced gastric cancer with&#xD;
      peritoneal metastasis.&#xD;
&#xD;
      Study hypotheses: Intraperitoneal paclitaxel administered to subjects at the recommended&#xD;
      phase 2 dose will show manageable safety and tolerability and anti-tumor efficacy with&#xD;
      systemic capecitabine and oxaliplatin in advanced gastric cancer with peritoneal metastasis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 8, 2021</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>6-month progression free survival (6-month PFS)</measure>
    <time_frame>6 months after start of treatment</time_frame>
    <description>PFS is the time from date of first dose until the date of objective disease progression or death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1-year overall survival (1-year OS)</measure>
    <time_frame>1 year after start of treatment</time_frame>
    <description>OS is the time from date of first dose until death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>6 months after start of treatment</time_frame>
    <description>Confirmed ORR per RECIST 1.1 is the percentage of patients with Complete Response or Partial Response that is subsequently confirmed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conversion surgery rate</measure>
    <time_frame>6 months after start of treatment</time_frame>
    <description>rate of conversion surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ascites response</measure>
    <time_frame>6 months after start of treatment</time_frame>
    <description>negative conversion rate of peritoneal cytology</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">61</enrollment>
  <condition>Stomach Neoplasms</condition>
  <condition>Paclitaxel</condition>
  <condition>Peritoneal Metastases</condition>
  <arm_group>
    <arm_group_label>Intraperitoneal paclitaxel + XELOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intraperitoneal paclitaxel Day1, Day8 + *XELOX&#xD;
*XELOX ; Capecitabine 2000mg/m2/day(Day1-14) Oxaliplatin 100mg/m2 IV Day1 q 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>intraperitoneal paclitaxel&#xD;
20mg/BSA(Body Surface Area), 40mg/BSA, 60mg/BSA (phase I)&#xD;
recommended dose (phase II)</description>
    <arm_group_label>Intraperitoneal paclitaxel + XELOX</arm_group_label>
    <other_name>capecitabine</other_name>
    <other_name>oxaliplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1. Inclusion Criteria:&#xD;
&#xD;
               -  ECOG(Eastern Cooperative Oncology Group) performance status 0 or 1&#xD;
&#xD;
               -  pathologically proven primary gastric adenocarcinoma&#xD;
&#xD;
               -  peritoneal metastasis confirmed by laparoscopy or diagnostic imaging&#xD;
&#xD;
               -  written informed consent&#xD;
&#xD;
               -  adequate function of important organs (within 14 days before registration)&#xD;
&#xD;
             Absolute neutrophil count ≥1.5 x 10^9/L, Platelet &gt;=100,000/mm3, Hemoglobin &gt;=8.0g/dL,&#xD;
             Total bilirubin &lt;= ≤ 2.0mg/dl or ULN(Upper Limit of Normal) x 1.5, AST(aspartate&#xD;
             aminotransferase) &lt;=100IU/L(International Unit/Liter), ALT(alanine transaminase)&#xD;
             &lt;=100IU/L, Creatinine clearance ≥ 50mL/min (milliliter/minute),&#xD;
&#xD;
          2. Exclusion Criteria:&#xD;
&#xD;
               -  other active concomitant malignancies&#xD;
&#xD;
               -  HER2(human epidermal growth factor receptor 2) positive (Immunohistochemistry 3+&#xD;
                  or 2+ with in situ hybridization positive)&#xD;
&#xD;
               -  no investigational anticancer therapy within 30 days prior to the first dose of&#xD;
                  study treatment&#xD;
&#xD;
               -  recent (within 6 months) acute coronary syndrome, severe heart failure or severe&#xD;
                  pulmonary disease&#xD;
&#xD;
               -  uncontrolled acute or chronic disease&#xD;
&#xD;
               -  uncontrolled infection or inflammation&#xD;
&#xD;
               -  uncontrolled psychiatric disorder or central neurologic disease&#xD;
&#xD;
               -  not fully recovered from previous surgery&#xD;
&#xD;
               -  prior anticancer therapy (chemotherapy, immunotherapy, radiation) within 6 months&#xD;
&#xD;
               -  intolerable to oral administration or a lack of physical integration of the upper&#xD;
                  gastrointestinal tract or with a malabsorption syndrome&#xD;
&#xD;
               -  fertile males and females who are unwilling to use effective contraceptive&#xD;
                  methods.&#xD;
&#xD;
               -  pregnancy, breast feeding or intention to become pregnant&#xD;
&#xD;
               -  interstitial pneumonia or pulmonary fibrosis&#xD;
&#xD;
               -  peripheral neuropathy with functional impairment&#xD;
&#xD;
               -  hypersensitivity to paclitaxel, oxaliplatin, capecitabine, fluoropyrimidine or&#xD;
                  Cremophor EL.&#xD;
&#xD;
               -  concomitant therapy with any substrate or inhibitor of Cytochrome P450 2C8 or 3A4&#xD;
&#xD;
               -  concomitant therapy with sorivudine or brivudine&#xD;
&#xD;
               -  Dihydropyrimidine dehydrogenase (DPD) deficiency.&#xD;
&#xD;
               -  current or recent (within the 7 days prior to enrollment) treatment of&#xD;
                  tegafur-gimeracil-oteracil potassium&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kabsoo Shin</last_name>
    <phone>82-2-2258-6256</phone>
    <email>kabsoo.shin@catholic.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gastric cancer center, Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kabsoo Shin</last_name>
      <phone>82-2-2258-6256</phone>
      <email>kabsoo.shin@catholic.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 21, 2021</study_first_submitted>
  <study_first_submitted_qc>June 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2021</study_first_posted>
  <last_update_submitted>July 1, 2021</last_update_submitted>
  <last_update_submitted_qc>July 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul St. Mary's Hospital</investigator_affiliation>
    <investigator_full_name>In-ho Kim</investigator_full_name>
    <investigator_title>Associate proffessor</investigator_title>
  </responsible_party>
  <keyword>Oxaliplatin</keyword>
  <keyword>Capecitabine</keyword>
  <keyword>XELOX</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

